COPD
AstraZeneca’s Trixeo approved in EU for asthma in patients aged 12 and over
October 27, 2026Asthma & COPD, COPD, EMA, EU, Pharmacy, asthma
AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved by the European Commission as a maintenance treatment for asthma in …
How will biomarker-led diagnostics reshape respiratory medicine?
October 11, 2026Asthma & COPD, COPD, Chronic Diseases, Diagnostics, biomarkers, clinical trial
By Dr Louise Ryan Murphy, Chronic obstructive pulmonary disease (COPD) is typically diagnosed and assessed through symptoms, lung function and …
Five Facts about COPD
October 11, 2026Medical Communications Asthma & COPD, COPD, Five Facts, HRT, Smoking Cessation, chronic bronchitis, emphysema, smoking
1 Chronic obstructive pulmonary disease is a group of progressive lung conditions, principally emphysema and chronic bronchitis, that restrict airflow …
AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials
October 4, 2026Asthma & COPD, COPD, asthma, clinical trials, monoclonal antibodies
AstraZeneca’s tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) in two phase 3 trials, cutting exacerbation …
Dupixent approved as first biologic medicine in Japan for COPD patients
April 2, 2025Research and Development COPD, Chronic Diseases, Regeneron, Sanofi, biotech, respiratory disease
The Ministry of Health, Labour and Welfare in Japan has authorised marketing and manufacturing of Dupixent (dupilumab) for the treatment …
Verona Pharma to share phase 3 COPD trial data at ATS 2024
May 2, 2024Medical Communications COPD, Cardiology, clinical trial, verona pharma
Verona Pharma has announced that it will share eight posters at the American Thoracic Society International Conference (ATS) 2024, including …
Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment
November 27, 2023Medical Communications COPD, Cardiology, Dupixent, Sanofi, clinical trial
Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for Dupixent as a treatment for …
Verona Pharma submits FDA New Drug Application for COPD treatment
June 27, 2023Research and Development COPD, Cardiology, FDA, ensifentrine, new drug application, verona pharma
UK-based Verona Pharma has announced that it has submitted a New Drug Application (NDA) to the US Food and Drug …
European approval for AstraZeneca’s Trixeo Aerospace in moderate to severe COPD
December 14, 2020Sales and Marketing AstraZeneca, COPD, EMA, Europe, Trixeo Aerosphere
The European Medicines Agency (EMA) has announced the approval of AstraZeneca’s Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) in the European Union …
AstraZeneca’s triple combination therapy for patients with COPD approved in China
December 23, 2019Sales and Marketing AstraZeneca, COPD, China, respiration
AstraZeneca has announced that budesonide-glycopyrroniunm-formoterol fumarate has been approved in China for the maintenance treatment of chronic obstructive pulmonary disease …
Living in polluted city for ten years increases risk of lung disease as much as pack of cigarettes a day for 29 years
August 14, 2019Research and Development Air pollution, COPD, lung disease, pharma emphysema, public health
Air pollution in cities dramatically increases the risk for and risk of progression of emphysema, a form of chronic obstructive …
Breathing life into COPD research
March 21, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COPD, GSK, feature
Alison Hollands, Vice President, Respiratory, UK Pharmaceuticals at GlaxoSmithKline, addresses the importance of implementing the latest approaches to treating COPD …
Mylan’s Wixela becomes first FDA-approved generic version of GSK’s Advair inhaler
January 31, 2019Sales and Marketing Advair, COPD, FDA, Wixela, asthma, generic, pharma
Mylan’s Wixela has become the first generic version of GlaxoSmithKline’s Advair Diskus (fluticasone propionate and salmeterol inhalation powder) inhaler to …
Verona’s shares drop 34% on Phase 2 failure of nebulised ensifentrine in COPD
January 15, 2019Manufacturing and Production, Research and Development Boehringer, COPD, Stiolto Respimat, pharma, trial failure, verona pharma
Verona Pharma has seen its shares crater following the Phase 2 failure of its nebulised ensifentrine, known as RPL554, in …
GSK’s Nucala data insufficient for US COPD approval
September 10, 2018Sales and Marketing COPD, FDA, GSK, Nucala, US, pharma
GlaxoSmithKline has suffered a regulatory blow in the label expansion of its interleukin-5 (IL5) inhibitor Nucala (mepolizumab), with the FDA …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
Dermatology leader Doncker is new Onicor CEO
